Vismodegib
Vismodegib is a pharmaceutical drug with 68 clinical trials. Currently 15 active trials ongoing. Historical success rate of 77.1%.
Success Metrics
Based on 37 completed trials
Phase Distribution
Phase Distribution
23
Early Stage
41
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
72.5%
37 of 51 finished
27.5%
14 ended early
15
trials recruiting
68
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Vismodegib in Treating Patients With Advanced Chondrosarcomas
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Clinical Trials (68)
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
Vismodegib in Treating Patients With Advanced Chondrosarcomas
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
The Drug Rediscovery Protocol (DRUP Trial)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 68